Skip to main content
Clinical Trials/ITMCTR2200006379
ITMCTR2200006379
Not yet recruiting
未知

A randomized controlled trial of combined pathological evidence and lifestyle intervention for the treatment of phlegm-damp internal obstruction type borderline hypertension

Eye Hospital of China Academy of Chinese Medical Sciences0 sitesTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Borderline Hypertension
Sponsor
Eye Hospital of China Academy of Chinese Medical Sciences
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Eye Hospital of China Academy of Chinese Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • ?No antihypertensive medication in the last 4 weeks and three consecutive upper limb brachial artery sitting blood pressure measurements on non\-same day within 1 week, systolic blood pressure (SBP) 120\-139 mmHg and/or diastolic blood pressure (DBP) 80\-89 mmHg.
  • ?Age 18\-65 years old, gender not limited.
  • ?Meet the diagnostic criteria of phlegm\-dampness internal obstruction evidence.
  • ?Voluntary participation and cooperation with the investigator by signing the written informed consent.

Exclusion Criteria

  • ?People with definite primary and secondary hypertension.
  • ?Participating in other clinical researchers.
  • ?People with borderline hypertension who are taking western antihypertensive drugs.
  • ?People with acute coronary syndrome, acute attack of chronic heart failure, malignant arrhythmia, heart valve disease, cardiomyopathy and other serious cardiovascular diseases.
  • ?People with acute or severe cerebrovascular diseases such as cerebral hemorrhage, subarachnoid hemorrhage, cerebral infarction and transient ischemic attack.
  • ?People with severe liver or kidney dysfunction and conditions judged by the investigator to be inappropriate for enrollment.
  • ?Pregnant and lactating women.
  • ?Allergic or allergic to multiple drugs.

Outcomes

Primary Outcomes

Not specified

Similar Trials